Key highlights
- NCLAT found a plausible pre-existing dispute over all three invoices totalling Rs 2.18 crore.
- The claim included two Rs 98.83 lakh milestone invoices and Rs 20.38 lakh in laboratory testing charges.
- Emails dated from 21 July 2023 to 9 August 2024 predated the 23 October 2024 demand notice.
- NCLAT held that the CIRP admitted on 9 September 2026 could not stand and ordered management restoration.
powered by IRIS
FTF Pharma’s Rs 2.18 crore claim could not support insolvency proceedings because the National Company Law Appellate Tribunal found documented disputes over all three invoices before the October 2024 demand notice. The tribunal relied on correspondence from July 2023 to August 2024 concerning testing costs, stability…